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ABSTRACT
The Beta ((3) thalassem ia syndromes are a 
heterogeneous group of genetic disorders. The 
frequency of thalassem ia is dependent on the 
ethnic origins of the patient population. Turkey is 
located in a geographic area of the world where 
thalassem ia syndrom es are common. The 
incidence rate of (3-thalassemia carriers was 
stated to be 2 per cent in Turkey. Clinical 
manifestations are d iverse and range from 
asymptomatic hypochromia and microcytosis to 
profound anem ia leading to death in early 
childhood if untreated. Individuals who are 
homozygous for the (3-thalassemia genes have 
severe, transfusion-dependent anemia and are 
said to have (3-thalassemia major. Thalassem ia 
intermedia is a condition in which the degree of 
hemolysis is milder even though the patient may 
have a deficiency of both (3 genes. Therefore, 
thalassem ia intermedia is essentia lly  a 
descriptive term that refers to minimal or no need 
for transfusions. The presence of one normal 
gene in the heterozygotes usually leads to 
enough normal (3-globin chain synthesis so that 
the affected individuals are usually asymptomatic 
with only a mild anemia. This condition is referred 
to as (3-thalassemia minor or (3-thalassemia trait.
In this report clinical and laboratory findings of 13- 
thalassem ia syndrom es in childhood are 
reviewed.
Key Words: Beta thalassem ia, Childhood, 
Anemia, Hypocromic microcytic anemia
INTRODUCTION
The Beta ((3) thalassem ia syndrom es are a 
heterogeneous group of genetic disorders, all 
characterised by a lack of or decreased synthesis 
of (3-globin chain of Hb A (a 2 (32) (1).
Thalassem ia was not recognized as a clinical 
entity until 1925, when Thom as Cooley described 
a syndrome among children of Italian descent 
characterised by profound anem ia, 
splenomegaly, and bone deformities (2). The first 
two patients with (3-thalassemia major in Turkey 
were reported in 1941 (3).
Prevalence and Geographic Distribution
The frequency of thalassem ia is dependent on 
the ethnic origins of the patient population (1 ,4 ) . 
The geographic areas in which thalassem ia is 
prevalent closely parallel the regions in which P. 
falciparum m alaria w as formerly endem ic. 
Resistance  to lethal malarial infections by 
carrie rs of thalassem ia genes apparently 
represented a strong selective force that favored 
their survival in these areas of endemic d isease 
(5-7). About 3% of the world's population (150 
million people) carry (3 thalassem ia genes. These 
genes are particularly prevalent in inhabitants of
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Italy, G reece and Cyprus (8, 9). Turkey is located 
In a geographic area of the world where 
thalassem ia syndromes are common. The first 
report about the prevalence of (3-thalassemia 
carriers in Turkey w as published in 1971 in which 
the incidence rate w as stated to be 2 per cent 
(1 0 ) .Different studies noted a frequency 
variability, ranging between 3.4 (East Anatolia) 
and 11 per cent (Western Thrace and Antalya) in 
Turkey (11, 12).
The pathophysiology
The "globin" part of the hemoglobin 
predominating in adults (hemoglobin A) is 
composed of four chains, 2 a- and 2 3-chains 
(13, 14). The pathophysiologic mechanism in 
thalassem ia is related to an unbalanced 
synthesis of globin chains or 3 chains. Normally, 
the synthesis of a  and (3 chains is balanced, 
resulting in normal hemoglobin A (a 2 32)- An 
unbalanced synthesis of either chain can lead to 
a failure in the matching of these chains and a 
defect in hemoglobinization within erythrocytes. 
In homozygous 3-thalassem ia, there is an 
excess of a  chains (1, 15). Because of their great 
instability, free a  chains aggregate to form 
insoluble inclusions in bone marrow erythroid 
precursors, causing premature destruction of 
maturing erythroblasts within the marrow 
(ineffective erythropoiesis) as well as lysis of 
mature red cells in the spleen (hemolysis)(1).
There are two 3 genes. Deficiency of one leads 
to essentia lly  no significant hem olysis (3 
thalassem ia trait/thalassemia minor); deficiency 
of both genes leads to significant hemolytic 
anem ia (tha lassem ia major). Tha lassem ia 
intermedia is a condition in which the degree of 
hemolysis is milder even though the patient may 
have a deficiency of both 3 genes. Therefore, 
thalassem ia intermedia is essentia lly a 
descriptive term that refers to minimal or no need 
for transfusions (16-19).
Genetics of (3-thalassemia
The non-a genes reside on chromosome 11. The
3-thalassemias result from the interaction of a 
large number of different molecular defects in the 
(3-globin genes. Underlying genetic defects 
include total or partial deletions of globin chain 
genes, nucleotide substitutions, deletions, or 
insertions (1, 13, 18), which result in none ((3°) or 
small amounts (0-20 %) ((3+) of globin chain
synthesis. 3-Thalassemia trait refers to mutations 
in one of two 3-globin genes.
In contrast to the a-thalassemia syndromes, the
3-thalassem ias are rarely caused by major 
structural gene deletions. Most of the 3 
thalassemia syndromes result from one or more 
nucleotide substitutions or deletions in genes that 
are otherwise intact. The well-known clinical 
heterogeneity of the thalassemia syndromes is a 
reflection of the great heterogeneity of mutations 
affecting the globin genes. Using techniques 
such as, restriction endonuclease digestion, 
gene blotting studies, cloning and sequencing of 
beta-globin genes, examination of expression of 
mutant genes in tissue culture cells with the use 
of plasmid expression vectors, investigators have 
identified more than 150 different mutations (18). 
Different studies showed that the molecular basis 
of 3-thalassem ia in Turkey is quite 
heterogeneous and that more than 40 different 
mutations are responsible for the great variability 
in clinical expression of this disorder (20-24). The 
IVS-l-110 (G-A) mutation is the most common 3 
thalassemia defect in Turkey (20, 22).
Clinical Features of (3 Thalassemia 
Syndromes
Individuals who are homozygous for the 3- 
thalassemia genes (3+/3+ or 3°/3°) have severe, 
transfusion-dependent anemia and are said to 
have 3- thalassemia major (Table I). Children 
with thalassemia major usually develop signs 
and symptoms of severe anemia in the latter part 
of the first year of life when normal hemoglobin 
synthesis becomes increasingly dependent on 3- 
globin. On presentation, affected infants usually 
have pallor, poor growth and development, and 
abdominal enlargement (1, 16, 25). In the 
absence of transfusion therapy, the hemoglobin 
concentration slowly falls to 3 to 6 g/dl (26). The 
associated pathophysiologic changes resulting 
from the subsequent anem ia include 
splenomegaly, which may lead to hypersplenism, 
osteoporosis, and other skeletal and soft tissue 
changes associated with an expanded bone 
marrow, and iron overload resulting from a 
combination of enhanced gastrointestinal iron 
absorption and red cell transfusions (27, 28). 
Prominence of the cheek bones tends to obscure 
the base of the nose and to expose the upper 
teeth. Thickening of the cranial bones produces 
frontal bossing (28). These  disturbances of
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craniofacial growth constitute the thalassémie 
facies. The liver, heart, pancreas, pituitary, and 
other endocrine organs serve as the major sites 
of excessive iron deposition, which ultimately 
leads to damage and failure of these organs (1, 
16, 26).
The definition of thalassem ia intermedia is used 
to designate a less severe hemolytic anemia. 
Chronic transfusion therapy is not required 
except in association with intercurrent illness, 
and survival into adult life is the rule. These 
patients usually experience normal growth and 
development (1). However the phenotype of 
thalassemia intermedia can be variable ranging 
from mildly to severe ly  affected patients. 
Genetically, tha lassem ia intermedia is 
homozygous (3-thalassemia with alleviating 
factors such as inheritance of mild (3-thalassemia 
mutations ((3+/(3+), Hb F enhancing factors and 
co-inheritance of a-thalassem ia (29).
The presence of one normal gene In the 
heterozygotes ((3+/(3 or (3°/(3) usually leads to 
enough normal (3-globin chain synthesis so that 
the affected individuals are usually asymptomatic 
with only a mild anemia. This condition is referred 
to as (3- thalassem ia minor or (3- thalassemia trait
(30 ,31). The syndrome is almost a lw ays 
discovered accidentally during examination for 
unrelated symptoms or as a consequence of a 
study designed to characterize better the nature 
of symptomatic anemia in a family member. 
Failure to respond to therapy for presumptive iron 
deficiency anemia often leads to a diagnosis of 
thalassemia trait. There is no enlargement of the 
liver or spleen in (3-thalassemia trait. 
Organomegaly suggests a more severe form of 
thalassemia.
The term thalassem ia minima described the 
situation in individuals who, although obligate 
carriers of a thalassem ia gene, had neither 
anemia nor abnormal red cell morphology. Each 
of these clinical phenotypes encom passes a 
heterogeneous group of genetic disorders 
including inheritance of heterozygous state for 
some types of mild (3-thalassemia mutations 
((3+/(3+). It is undetectable except by inference 
from family studies (16, 32, 33).
Laboratory Features and Definitive Diagnosis 
of (3 Thalassemia Syndromes
In p Thalassem ia major, the anemia is severe 
and first becomes manifest 6 to 9 months after 
birth, as hemoglobin synthesis switches from Hb 
F to Hb A. In untransfused patients, hemoglobin 
levels range between 3 and 6 gm/dl (1, 16, 26). 
The peripheral blood sm ear show s severe 
abnorm alities; there is marked anisocytosis 
(variation in size) with many small and virtually 
colorless (microcytic, hypochromic) red cells. 
Abnormal forms, including target cells, stippled 
red cells, and fragmented red cells, are common. 
Inclusions representing aggregated a  chains are 
removed by the spleen and hence are not visible 
in peripheral blood (34). The reticulocyte count is 
elevated, but because of ineffective 
erythropoiesis, it is lower than would be predicted 
from the severity of anem ia (26). Variable 
numbers of poorly hemoglobinized normoblasts 
are seen in the peripheral blood. The red cells 
contain either no Hb A at all (P° /p° genotype) or 
small amounts ((3+/p+ genotype) (0 to 20%) (16). 
Hb F is markedly increased (20-100%) and 
indeed constitutes the major hemoglobin of red 
cells (1, 16). Hb A2 levels may be normal, low, or 
high (2 to 7%). W BC counts are often mildly 
increased, and there may be mild granulocytic 
immaturity, sometimes even with myelocytes 
present (26). Platelets are normal. Increased 
unconjugated bilirubin levels and other 
biochemical evidence of hemolysis can be found. 
The urine often contains increased quantities of 
urobilin or urobilinogen and may be dark brown 
because of the presence of dipyrroles and 
mesobilifuscin (26). The results of ferrokinetic 
studies are in keeping with ineffective 
erythropoiesis; plasma iron turnover is increased 
out of proportion to the increase in erythrocyte 
iron turnover. Serum iron levels are increased, 
serum transferrin is often fully saturated, and a 
non- transferrin-bound iron fraction may be 
present. The osmotic fragility of red corpuscles is 
strikingly decreased . The bone marrow is 
rem arkably hypercellular with profound 
normoblastic hyperplasia. Deficient hemoglobin 
content of red cell p recursors, as well as 
cytoplasmic inclusions, is apparent (1, 16, 26).
In thalassem ia intermedia, parental studies 
reveal the anemia and microcytosis. However, 
baseline hemoglobin concentration is higher than 
thalassem ia major with a range of 6 to 9 g/dl
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without transfusion (26). Peripheral blood 
erythrocytes show changes comparable to those 
of thalassem ia major: significant anisocytosis, 
hypochromia, target cells, basophilic stippling, 
and numerous nucleated forms. Bone marrow 
hyperplasia is prominent and inclusions of 
denatured a  chains can be demonstrated in late 
normoblasts by using supravital stains (34). The 
hemoglobin electrophoretic pattern is highly 
variable, a reflection of the heterogeneity of 
genotypes producing this clinical syndrome. 
Other laboratory features are derivatives of 
accelerated heme turnover and iron overload.
Infants destined to develop thalassem ia minor 
are hematologically normal at birth. By 4 months, 
the hemoglobin concentration, MCV, MCH, Hb 
A2 and Hb F levels are all outside normal ranges
(35) .The postnatal decline in Hb F is delayed, 
and the normal increase in Hb A2 is accelerated
(36) . Anemia is mild or absent. The hemoglobin 
concentration rem ains approxim ately 2 g/dl 
below normal standards but parallels the normal 
upward trend during, childhood. The red cell 
count is elevated, and the MCV and MCH values 
are reduced. The degree of reduction in the MCV 
is directly related to the degree of reduction in (3- 
globin production (36). The MCVs produced by 
P° mutations are lower than those produced by 
P+ mutations. Co-inheritance of a p° thalassemia 
gene and a  thalassem ia (one or two a-globin 
gene deletion) normalizes the red cell indices but 
not the level of Hb A2 (37, 38). The MCHC is 
normal or only slightly decreased . In contrast to 
the minor degree of anem ia, morphologic 
alterations of peripheral blood erythrocytes are 
prominent. These changes include microcytosis, 
hypochromia, anisocytosis, poikilocytosis, target 
cells, and basophilic stippling Nucleated R B C s 
are not present. The reticulocyte count is 
frequently elevated. The osmotic resistance of 
erythrocytes is strikingly increased. Erythrocyte- 
free protoporphyrin usually is normal, in contrast 
to elevated levels in iron deficiency (39, 40). The 
most consistent feature of heterozygous Pj and 
P+ thalassem ia is an increase in Hb A2 (A2 is not 
elevated in a  thalassem ia trait). A2 is a variant of 
adult Hb A and is normally present in quantities 
up to 2 .5%  or 4% , depending on the method 
used. In p thalassem ia trait, A2 is elevated to 
some degree with a maximum of approximately 
10% . More than 90%  of persons with p- 
thalassem ia trait have diagnostic elevations of
Hb A2 of 3.4-7%. Hemoglobin F is usually normal 
but can be present in quantities up to 5%. 
Hemoglobin A2 cannot be identified on paper 
electrophoresis, and demonstration or 
quantitation necessitates cellulose acetate or 
polyacrylamide gel electrophoresis or resin 
column methods. Chronic iron deficiency 
decreases Hb A2 levels so that iron deficiency 
coexistent with p thalassemia trait could lead to 
falsely normal Hb A2 results (41). Thalassem ia 
minor is easily confused with mild iron deficiency 
(Table II). Several simple observations 
distinguish the two conditions. W hereas 
microcytosis, hypochromia, anisocytosis, and 
poikilocytosis are minimal in iron deficiency at a 
hemoglobin concentration of 10 to 11 g/dl, they 
are conspicuous features of the blood sm ear in 
patients with thalassem ia trait having 
comparable levels of hemoglobin. Basophilic 
stippling and an increase in the icterus index are 
also prominent, w hereas iron deficiency is 
associated with little or no stippling and with a 
decrease in serum bilirubin level. Several 
discriminative functions have been developed to 
facilitate differentiation of the two disorders on 
the basis of routine blood counts (42). Patients 
who have p-thalassemia trait, in contrast to those 
who have iron deficiency, typically have an 
increased number of red cells that are smaller 
than normal, leading to a ratio of the MCV/red 
cell count per milliliter of less than 13. The ratio in 
iron deficiency is usually more than 13 (Mentzer 
index) (43). The coefficient of variation of red cell 
size  is higher in iron deficiency than in 
thalassemia minor, a derivative readily generated 
by electronic cell counters (44). Laboratory 
assessm ent of iron status can be used to 
differentiate p thalassem ia trait and iron 
deficiency (Table II). Bone marrow iron is absent 
in iron deficiency and normal or increased in p- 
thalassemia trait. Patients with p thalassemia 
trait may have concurrent chronic iron deficiency 
and anem ia of chronic d isease  may be 
concurrent with either condition. The anemia of 
chronic disease may itself be microcytic and 
hypochromic in some cases (1).
Silent p thalassemia is inferred in the ostensibly 
normal parent of a child with thalassem ia 
intermedia if the other parent has high-Hb A2 
thalassemia minor. The MCV and MCH values 
are normal or only minimally decreased and the 
hemoglobin pattern is normal. The condition can
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be established with certainty only by globin chain 
synthesis studies, which show an a:p-globin 
chain ratio of approximately 1.3 (32).
Screening for |3-thalassemia
Ideally, thalassemia carriers should be detected 
as part of a screening programme, such as 
premarital screening in Cyprus (9) and Sardinia 
(45), or during early pregnancy in most 
Mediterranean countries. This allows screening 
of the partner and if the couple are both carriers 
then prenatal diagnosis will be possible. In 
particular, the finding of a non-iron-responsive 
microcytic anemia in the pregnant woman should 
prompt a careful evaluation for thalassem ia trait 
that, if present, should lead to a sim ilar
evaluation of the father. This approach permits 
the family to consider in utero diagnosis. Fetus of 
heterozygote parental pairs can be screened for 
homozygous thalassem ia in utero employing 
DNA analysis of a chorionic villus biopsy at 8-10 
weeks or amniotic fluid cells from amniocentesis 
at 16-18 w eeks (46, 47). The em phasis is 
prevention of an affected birth by giving the 
parental pair the choice of terminating an 
affected pregnancy, and this can only be done by 
early detection of the carriers. A previous study 
dealing with prenatal diagnosis of (3 thalassem ia 
in Turkey has indicated that prenatal diagnosis is 
feasible in Turkey when early methods of fetal 
sampling are combined with the advent of PCR- 
based techniques (24).
T a b le  I: Clinical and Hematologic Features of the (3 Thalassemia Syndromes
Nomenclature (3 Thalassemia Major/ 
Homozygous (3 Thalassemia
(3 Thalassemia Intermedia (3 Thalassemia Minor/ 
Heterozygous (3 Thalassemia
Genetics (3° /(3°
P* /P+ 
P°/p'
Homozygous |3-thal. inheritance 
of p+ /(3+ mutation, 
Coinheritance of cc thal.
Hb F enhancing factors
(30 /|3
P+/P
Clinic Severe anemia
Requires blood transfusions regularly
Moderately severe anemia,
does not require regular blood transfusions
Asymptomatic child with 
mild or absent anemia
Hematologic features Normoblastemia
Microcytosis,
Hypochromia
Anisocytosis
Poikilocytosis
Basophilic stippling
Fragmented red cells
Normoblastemia
Microcytosis,
Hypochromia
Anisocytosis
Poikilocytosis
Basophilic stippling
Fragmented red cells
Microcytosis, 
Hypochromia 
Anisocytosis 
Poikilocytosis 
Basophilic stippling
Anemia (Hb) (g/dl) 3-6 6-9 9-10
(3°: Mutations that lead to a decreased level of normal (3-chain production 
(3+: Mutations that lead to absence of normal (3-chain production 
Thai.: Thalessemia
T a b le  II: Differential Diagnosis of Iron deficiency and Beta 
Thalassemia Trait
Iron deficiency Beta Thalassemia Trait
MCV Low Very Low
Serum iron Decreased Normal
TIBC Increased Normal
Trans. Sat. Decreased Normal
FEP Increased Normal
Serum Ferritin Decreased Normal
Hb A2 Normal Increased
MCV: Mean Corpuscular Volume, TIBC: Total Iron Binding Capacity, 
Trans. Sat: Transferrin iron saturation, FEP: Free erythrocyte porphyrin 
Hb: Hemoglobin
CONCLUSION
Appropriate screening and subsequent 
diagnostic testing will allow the family physician 
to diagnose most cases of anemia in children . If 
there is a question about the diagnosis, the 
genetics, appropriate counseling, or subsequent 
evaluation, children suspected of having 13- 
thalassem ia should be referred to a pediatric 
hematologist. Th ese  would include patients 
whose anemia is more severe than would be 
expected; they may have a confounding second
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reason for anem ia or they may have 13- 
thalassem ia intermedia, (3-thalassemia major, 
which present more complex diagnostic and 
therapeutic problems.
Although there are excellent treatment modalities 
today, there is no definitive cure for (3- 
thalassem ia yet with the exception of bone 
marrow transplantation, which is not available to 
most patients. Until novel therapies, such as Hb 
F reactivation and gene therapy becomes a 
reality, the only approach to the control of 
haemoglobinopathies is prevention. Avoidance 
of consanguineous marriage, which is 21.21%  in 
Turkey (48), will a lso help to significantly 
decrease the frequency of affected births. The 
most important challenge for the eradication of 
the haem oglobinopathies in Turkey is the 
organization of a national genetic preventive 
programme for the eradication of (3-thalassemia, 
like those going on in several high-risk areas of 
the Mediterranean basin such as Cyprus and 
Sardinia. Th is could be performed either as 
premarital screening of reproductive couples (49) 
or by education of the population at risk and their 
physicians.
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